Crescendo's CLIA-certified test measures 12 different biomarkers common to rheumatoid arthritis, giving doctors a starting point from which to assess how a patient is doing at a given point in time.

South San Francisco-based Crescendo Bioscience has raised $56 million as a result of completing a $31 million Series C equity financing round and entering an investment agreement with Myriad Genetics ...